Men from deprived areas less likely to be treated for prostate cancer

April 22, 2010

Men living in deprived areas are far less likely to be treated with the most common types of radical treatment for prostate cancer than those in more affluent places, says a study published in the British Medical Journal today.

A large scale study carried out by researchers from Cambridge found that patients from the most deprived areas are 26% less likely to have radiotherapy than men from the most affluent areas and 52% less likely to have radical surgery.

is the most common in men and its incidence has been increasing, particularly since the late 1980s and early 1990s.

It is 20-40% more likely to happen and be noted in the most affluent areas and survival rates are also increasing to around 80% in that same socioeconomic group. It is thought this is partly due to less deprived men agreeing to prostate specific antigen (PSA) screening tests.

The researchers, led by Georgios Lyratzopoulos at the University of Cambridge, studied data on 35,171 men (aged 51 and over) between 1995 and 2006.

More detailed information about the stage of their disease was available for 15,916 men over a nine-year period from 1998 to 2006.

The men were all diagnosed with prostate cancer during this period and the researchers sought to find out what variation existed in how the cancer was managed between patients of different .

The proportion of patients treated by surgery increased significantly over time from 2.9% during 1995-7 to 8.4% during 2004-6. Use of radiotherapy for patients remained stable at around 25% throughout the study period.

The researchers found that either radiotherapy or surgery was used more often in the most affluent people.

was used for the most affluent people in 28.5% of cases, compared with 21% of people from the most deprived areas - a 26% difference. Similarly, surgery was used for 8.4% of the better off people, compared with just 4% of the worse off patients - a 52% difference.

This pattern persisted even when factors such as age, hospital of diagnosis and disease stage were taken into consideration.

The researchers say the causes and impact on survival of such differences between socioeconomic groups remain uncertain, and call for further research to help explain the socioeconomic differences in treatment.

In an accompanying editorial, researchers in Finland suggest that, when discussing treatment decisions, "better educated patients may process information more easily and doctor-patient communication may be more effective or fluent when doctor and patient have similar social backgrounds."

Because the reasons for these socioeconomic disparities are unclear and the best way to reduce them is unknown, future studies should investigate the contribution of various prognostic factors to differences in survival, they conclude.

Related Stories

Recommended for you

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

Liquid biopsy results differed substantially between two providers

December 14, 2017
Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers. Liquid biopsy is a new and noninvasive alternative ...

Testing the accuracy of FDA-approved and lab-developed cancer genetics tests

December 14, 2017
Cancer molecular testing can drive clinical decision making and help a clinician determine if a patient is a good candidate for a targeted therapeutic drug. Clinical tests for common cancer causing-mutations in the genes ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.